Finanzen von Achieve Life Sciences, Inc. (ACHV)ACHVAchieve Life Sciences, Inc.

Evaluating the bottom line, Achieve Life Sciences, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -844.99%, provide a clear picture of how effectively ACHV converts its operational activities into shareholder value.

In the context of the broader market, ACHV competes directly with industry leaders such as SGMT and IMMX. With a market capitalization of $718.62M, it holds a significant position in the sector. When comparing efficiency, ACHV's gross margin of N/A stands against SGMT's N/A and IMMX's N/A. Such benchmarking helps identify whether Achieve Life Sciences, Inc. is trading at a premium or discount relative to its financial performance.

The company has reported consistent losses, with a net income of -74,769,000 USD in Q2 2026 and an EPS of -0.80 expected for the next quarter. Despite these losses, the current ratio is 0.95, indicating potential liquidity issues, but the company has a strong market position with its drug development.